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Recent progress in our understanding of the immunologic 
basis of allergic diseases has suggested that enhanced produc-
tion of the cytokines IL-4 and IL-13 by allergen-specific T 
cells is responsible for increased IgE synthesis and the devel-
opment of allergic disease in certain individuals. Based on 
these observations, it is clear that approaches to inhibition of 
allergen-specific IgE synthesis should be aimed at blocking 
the activation or preventing the synthesis ofIL-4 and IL-13. 
In the present review, two approaches toward this goal are 
discussed. 
First, an IL-4 mutant protein is described that acts as a 
powerful antagonist of both IL-4 and IL-13 activity, includ-
ing induction of IgE synthesis by these cytokines in vitro. 
A llergen-specific IgE antibodies play an important role in mediating allergic reactions. They bind to high-af-finity IgE receptors (FCERI) expressed on mastcells and basophils. Binding of allergens to this receptor-bound IgE results in receptor activation that triggers 
the mastcells/basophils to release soluble mediators such as hista-
mines, leukotrienes, prostaglandins, and proteases, which cause al-
lergic reactions in various target organs, including the eyes, respira-
tory tract, intestines, and skin. 
Early studies have shown that Ig production, including IgE syn-
thesis, is T-helper-cell dependent [1], but only recently it has be-
come clear that cytokines play an important role in Ig production 
[2]. They determine Ig production quantitatively through their 
B-cell growth and differentiation inducing effects. In addition, cy-
tokines direct the quality of the Ig isotype produced, because they 
determine Ig isotype switching. For example, the T-cell-derived 
interleukins (IL)-4 and IL-13 induce human B cells to produce 
IgG4 and IgE [3], whereas TGF-fi induces IgA switching [4]. In 
addition to cytokines, contact-mediated co-stimulatory signals de-
livered by activated CD4+ T -helper cells are required for induction 
of Ig production both in vitro and in vivo [5]. 
In the present communication, cellular and molecular aspects 
of induction and regulation of human IgE synthesis and the role 
of allergen-specific T cells and cytokines produced by these cells 
will be discussed. In addition, novel approaches to intervene in 
early stages of the regulatory processes, which lead to induction 
of IgE synthesis, and their potential clinical utility will be des-
cribed. 
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Second, it is demonstrated that T-cell clones can be rendered 
non-responsive following incubation with allergen-derived 
peptides representing minimal T-cell activation-inducing 
epitopes. These non-responsive T cells fail to produce IL-4 
and IL-13 and to proliferate following subsequent activation 
with the relevant allergen and antigen-presenting cells. In 
addition, these non-responsive T cells fail to provide B-cell 
help for IgE synthesis. It is tempting to speculate that induc-
tion of non-responsiveness in allergen-specific T-cell clones 
by allergen-derived immunogenic peptides may provide the 
basis for successful desensitization of allergic patients.] [,west 
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lL-4 AND IL-13 INDUCE IGG4 AND IGE SYNTHESIS 
B cells undergo Ig isotype switching and differentiation into Ig 
secreting cells in response to antigens that specifically bind to sur-
face IgM receptors and co-stimulatory signals delivered by CD4+ 
T -helper cells. Antigen-specific T -B interactions require binding of 
the T-cell receptor to peptide class II major histocompatibility anti-
gens (MHC) complexes on the B cells, which results in T-cell 
activation and cytokine production. Once T-helper cells are acti-
vated, they can stimulate B cells to proliferate and to differentiate in 
an antigen-dependent fashion. Cytokines play an essential role in 
these processes. IL-4, which is produced by T cells and mast-cells, 
induces IgE synthesis in cultures of mononuclear cells of peripheral 
or cord blood, tonsils, and spleens [3]. Single naive surface IgM+, 
IgD+ B cells can be induced to produce IgG4 and IgE, in the pres-
ence of activated CD4+ T -helper cells and IL-4, indicating that 
IgG4 and IgE production reflects Ig isotype switching [6]. In addi-
tion, these data suggested that during clonal expansion switching of 
a proportion of the B cells may proceed in two successive steps: from 
IgM to IgG4 and from IgG4 to IgE. The fact that Ig production in 
these cultures is restricted to IgM, IgG4, and IgE furthermore indi-
cates that isotype switching is not a stochastic process but is directed 
by the way the B cells are activated. 
Recently, we cloned, expressed, and characterized another 
T-cell-derived cytokine, IL-13 [7], which was found to induce 
IgG4 and IgE production by human B cells in an IL-4- independent 
manner [8]' Interestingly, mouse IL-13 failed to induce IgE synthe-
sis by mouse B cells in culture systems where IL-4 was effective. 
This is compatible with the observation that mice in which the IL-4 
gene is disrupted by homologous recombination fail to produce IgE 
following parasite infections [9]. Thus IL-13 is only effective in 
inducing human IgE synthesis. Whether this implies that IL-13 
plays a unique role in inducing IgE-mediated allergic diseases re-
mains to be determined and depends on the relative contributions of 
lL-13 and IL-4 to this process. 
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IL-4/IL-13-INDUCED IgE ,SYNTHESIS REQUIRES 
CO-STIMULATORY SIGNALS PROVIDED 
BY T-B CELL CONTACTS 
In addition to cytokines, contact-mediated co-stim';llatory ~ignals 
delivered by activated CD4+ T -helper cells are requtred for mduc-
tion ofIg production in vivo [5,10,11]. These T-B ~ell contacts are 
mediated through interactions between the CD40 hgand (CD40L) 
(which is transiently expressed on activate~ T cells) and CD.40 
(constitutively express~d on B cel~s) . Produc~1ve.CD.40~-CD4~ m-
teractions are also requtred for Ig 1sotype sW1tchmg In VIVO. Patients 
with the hyper IgM syndrome, who have normal, or enhanced 
serum IgM levels, but Ilone, or low levels, of the other .Ig isotypes 
have mutations in their CD40L genes that lead to defective CD40L 
expression and non-productive CD40L-~D4.0 in~eractions, v:hich 
accounts for the defective Ig-isotype sW1tchmg m these patients. 
Patients with hyper IgM syndrome have normal B cells that can 
easily be induced to Ig isotype switching. and Ig isotype production 
in vitro by crosslinking of CD40 by anti-CD40 mono~lonal anti-
bodies, or transfectants expressing "normal" CD40L m the pres-
ence of the relevant cytokines [12-15]' 
IgE SYNTHESIS IN VIVO 
Murine studies have indicated that IL-4 is responsible for IgE pro-
duction in vivo, because parasite-infected mice treated with neutral-
izing anti-IL-4 antibodies failed to produc~ IgE [16]. Howeve~, no 
circulating IL-4 or IL-13 could be detected.m .the ~er~m of p~tients 
with very high serum IgE levels, but convmcmg md1rect. eV1?enCe 
has been obtained, indicating that enhanced IL-4 production 1S also 
associated with elevated serum IgE levels in humans [17]. For exam-
ple, peripheral blood mononuclear cells (PBMe) of som~ pa~ients 
with high serum IgE ~evels spontaneously produce IL-4 In vI,tr~, a 
phenomenon that is never observed wit~ PBMC of non-atop1c m-
dividuals. In addition, PBMC of such patients produce levels ofIL-4 
following activation that are significantly higher than those pro-
duced by PBMC of normal control donors [16]. t:he fail':ll'e to.dete~t 
measureable levels of circulating IL-4 and IL-13 m atop1c patients 1S 
probably related to the fact th~t these ~ytokines are biologi~a~ly 
active at femtomolar concentrations, wh1ch are below the sens1t1v-
ity of, the detection assays and that they are predominan,tly pro-
duced at the site of allergic reactions. Indeed, T cells producmg IL-4 
and IL-5 have been identified in situ in skin biopsies taken from 
late-phase cutaneous reactions .in at~pic asthma I?atients [18] or in 
bronchial lavage fluids of atop1c patients, followmg allergen chal-
lenge [19]. . 
Recent information has shown that allergen-speCific T cells are 
responsible for the enhanced levels of IL-4 production in allergic 
patients. Allergen-specific CD4+ T cells established from allergic 
patients gen.erally ~elong to the T-helper cell 2 (Th2) subset, pro-
ducing relattvely h1gh levels ofIL-4, IL-5, and IL-13 and no, or low 
levels of, IFN-y after allergen-specific activation in vitro. Because of 
their IL-4 and IL-13 contents, supernatants of these T-cell clones 
induce B cells to synthesize IgG4 and IgE under the appropriate 
culture conditions in vitro. * 
MODULATION OF IN VITRO AND IN VIVO IgE 
SYNTHESIS BY CYTOKINES 
IL-4 and IL-13 are thus far the only cytokines that induce IgE 
synthesis. However, ma~y othe: cy~okines .can. modulate IL-4/IL-
13 - induced IgE syntheSlS both In vItro and In VIVO. IFN -y and IFN-
a, IL-8, IL-10, IL-12, and transforming growth factor (TGF}-P all 
inhibit IL-4 - induced IgE synthesis in vitro, whereas IL-5, IL-6, and 
tumor necrosis factor (TNF}-a have enhancing effects. The mech-
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anism by which these cytokines modulate IgE synthesis are still 
poorly understood and therefore will not be further discussed here. 
Interferon (IFN}-Y and IFN-a are also effective in reducing 
serum IgE levels in vivo. Administration of I~N-y o.r lPN-a to 
patients with the hyper IgE syndrome resulted m a rap1d, but tran-
sient, reduction in serum IgE levels, whereas the serum levels of the 
other Ig isotypes in these patients remained unaffected ~20,21]. !n 
the single patient treated with IFN-a, complete but translent remls-
sion of the skin lesions associated with this syndrome was observed, 
despite her serum IgE levels still being elevated as compared to those 
of normal controls [21]. Such case reports, however, indicate that 
the use of IFN-y and/or IFN-a for the treatment of severe atopic 
diseases, like atopic dermatitis, deserves further exploration. 
AN IL-4 ANTAGONIST INHIBITS BOTH IL-4 
AND IL-13-INDUCED IgE SYNTHESIS 
Although the relative contribution of IL-4 and IL-l3 to IgE pro-
duction ill vivo remains to be determined, it is clear that effective 
inhibition of IgE synthesis in vivo requires prevention or inhibition 
of both IL-4 and IL-13 production by allergen-specific T cells, or 
blocking of the activity of these cytokines by using specific IL-4 and 
IL-l3 antagonists. Recently an IL-4 mutant protein has been de-
scribed that binds with high affinity to the IL-4 receptor (IL-4R), 
without receptor activation [22,23]. Interestingly, this IL-4 mutant 
protein, in which the tyrosine residu~ at po~iti?~ 124 is replaced by 
an aspartic acid (IL-4.Yl24D), effectively mhlb1ts both IL-4- and 
IL-l3-induced IgG4 and IgE synthesis in vitro [24]. A lO-50-fold 
molar excess of IL-4.Y124D inhibited IgE synthesis by optimal 
IL-4 and IL-l3 concentrations by >95%, indicating that IL-4. 
Y124D acts as a powerful antagonist for both IL-4 and IL-13 activ-
ity. Although IL-13 competes with IL-4 for binding to functional 
IL-4R and vice versa, it does not bind to the cloned 130-kD IL-4 
receptor expressed on heterologous cells. In addition, the affinity of 
IL-4 for its functional "wild type" receptor is higher than that for 
the cloned IL-4R. These, and other data, have led to the conclusion 
that the IL-4 and IL-13R are complex receptors that share a com-
mon component, which confers high-affinity binding for IL-4, and 
which is required for signal transduction [23]. The observation that 
the IL-4 antagonist inhibited both IL-4 - and IL-13 - induced IgE 
production in vitro supports this notion. Therefore, antagonistic 
IL-4 mutant proteins may provide the most efficient way to reduce 
IgE synthesis in allergic patient~ and may have thera~eutical p.ote~­
tial for the treatment of allerg1es. However, more mformatlon 1S 
required regarding the stability and the effects of these molecules in 
vivo. 
INDUCTION OF NON-RESPONSIVENESS IN 
ALLERGEN-SPECIFIC T CELLS IN VITRO 
The most specific approach to prevent allergen-specific IgE synthe-
sis in vivo should be aimed at rendering allergen-specific T cells 
non-responsive to allergen challenge. Such non-responsive T cells 
will not proliferate and will not produce IL-4 and IL-13 in response 
to subsequent activation by allergen and antigen-presenting cells 
(APe), which will result in prevention of allergen-specific IgE syn-
thesis in vivo. 
The minimal requirement for an allergen-specific immune re-
sponse is effective binding ofT -cell receptors on allergen-specific T 
cells to allergen-derived peptide-class II MHC complexes on APC. 
Whether these T-cell-receptor peptide/MHC complex interac-
tions result in T-cell activation depends on co-stimulatory signals 
provided by "professional" APC. TCR-peptide/MHC complex in-
teractions in the absence of co-stimulatoty signals delivered by pro-
fessional APC renders these cells non-responsive to subsequent 
challenges by antigens and APC [25,26] . 
Human T cells can also be tolerized iI, vitro following activation 
with supra immunogenic doses of antigenic peptides in the absence 
of professional APC. Subsequent exposure of these ~olerize? T c~lls 
to antigens presented by APC does not result m prohferatton 
[27,32]. Because anergic T-cell clones fail to produce IL-2, de-
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creased production of this cytokine by the T cells has been proposed 
as the mechanism of clonal non-responsiveness [25,26]. 
Similar observations were made with allergen-specific human 
T-cell clones. Incubation of T -cell clones specific for the major 
house dust mite allergen Der pi with supra immunogenic doses of 
Der pI-derived pep tides (representing the minimal T-cell activa-
tion inducing epitopes) in vitro rendered these clones non-respon-
sive to subsequent stimulation by whole Der pi and APC. The non-
responsive state was associated with the strong downregulation of 
T-cell receptors, suggesting that in this situation reduced TCR ex-
pression may account for the non-responsiveness of these cells." 
The observation that stimulation of these T-cell clones via their 
TCR failed to induce significant intercellular Ca++ fluxes is com-
patible with this notion. In contrast to their non-tolerized counter-
parts, the "tolerized" Der pI specific T cells failed to produce cyto-
kines, including IL-4 and IL-13, and to induce IgE synthesis when 
co-cultured with purified B cells, indicating that these cells also lost 
their B-cell helper activity resulting in IgE switching and IgE pro-
duction. 
INDUCTION OF TOLERANCE IN VIVO 
Immunotherapy with immunogenic pep tides corresponding to im-
muno-dominant T-cell determinants administered to mice can in-
duce T-cell tolerance to subsequent challenge with native antigens 
in vivo. Such pep tides have recently been successfully used to treat 
autoimmune disease in mice. For example, tolerance-inducing regi-
mens for the treatment of myeloid basic protein induced autoim-
mune encephalitis (EAE), blocked the progression and decreased 
the severity of EAE, after the disease had begun. The peptide-in-
duced tolerance resulted from the induction of anergy in prolifera-
tive, antigen-specific T cells [32]. Comparable data have recently 
been obtained with allergen-derived peptides. Administration of 
two peptides, which contain some, but not all, T-cell epitopes on 
one of the chains of the cat allergen Fel dI also decrease the T-cell 
responses to this entire chain of Fel dl in mice [32]. 
PEPTIDE VACCINATION IN ALLERGIC PATIENTS 
The potential use of peptide induced T-cell tolerance as a means to 
treat severe human allergies is a consequence of these studies. The 
question, however, is how to proceed. As mentioned ~bove, aller-
gen-specific T-cell clones can be rendered non-responsive to subse-
quent allergen challenges it' vitro by incubation with supra immu-
nogenic doses of antigenic peptides in the absence of professional 
APC. In addition, traditional immunotherapy (IT) with standard-
ized allergen extracts seems to become more effective, when pa-
tients are desensitized with increasing (maximally tolerated) con-
centrations of allergens. Although it remains to be established, it is 
tempting to speculate that mechanisms resulting in peptide-induced 
allergen-specific T-cell non-responsiveness also may account for 
successful IT. Therefore, based on the present information, ideally 
one would like to administer high concentrations of allergen-der-
ived peptides, containing T-cell activation inducing epitopes, to 
bypass the professional APC and to " hit" the allergen-specific T 
cells directly and render them anergic. Theoretically this is feasible, 
because pep tides containing minimal T -cell- inducing epitopes do 
not react with specific IgE antibodies and do not induce histamine 
release from sensitized basophils, and thus are unable to induce 
anaphylactic reactions (H. Y ssel et al, unpublished). Therefore, such 
peptides seem to be ideal tools for inducing allergen-specific T-cell 
tolerance. A major problem, however, is that most, if not all, aller-
gens contain multiple T-cell activation inducing (T-cell epitopes) 
epitopes, which are restricted by various class II MHC molecules 
[33-35]. This implies that for each patient all "individual" T-cell 
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inducing epitopes should be determined together with precise 
human leukocyte antigen typing. Such an approach is, at this stage, 
impractical and cannot be carried out on a large scale for general 
treatment of allergies. However, the principles of this type of IT 
could be worked out in individual, well-defined patients. 
A more practical approach could be the use of overlapping pep-
tides of approximately 30 - 50 amino acids, representing whole 
known (recombinant) allergens that can be produced at an industrial 
scale. Assuming that such peptides contain all the T-cell epitopes of 
the corresponding allergen, administration of high concentrations 
of these mixtures of allergen-derived peptides seems feasible with-
out inducing anaphylaxis. The advantage of this approach is that it 
does not require mapping of minimal T-cell activation inducing 
epitopes. In addition, there is no necessity of class II MHC typing of 
the patients. One clinical trial, which is in part based on this type of 
approach, is presently in progress. In this trial, patients with cat 
allergies are treated with two Fel dl - derived peptides representing 
the immunodominant T-cell epitopes. 
CONCLUDING REMARKS 
Treatment of allergies is presently predominantly focused on late 
phases of the allergic response, namely, an inhibition of mediator 
release by mastcells or basophils or on blocking of binding of soluble 
mediators to their receptors. The present data indicate that en-
hanced IL-4 and IL-13 production by allergen-specific T cells is 
associated with enhanced allergen-specific serum IgE levels. There-
fore, it is clear that novel approaches to block IgE synthesis in an 
early stage should be aimed at the inhibition, or neutralization, of 
IL-4 and IL-13 production in vivo by using IL-4 and IL-13 antago-
nists like IL-4 mutant protein or derivatives thereof, described here. 
However, much more information is required about the stability of 
such antagonistic proteins and their activities it, vivo. 
The mechanisms by which high IL-4- and IL-13-producing 
allergen-specific CD4+ T cells are selected in atopic patients re-
mains to be elucidated. A better understanding of these selection 
mechanisms will enable us to define ways to intervene in these 
processes, and to reduce the frequencies of high IL-4- and IL-13-
producing T cells. One possible way is to render these T cells non-
responsive by administration of mixtures of allergen-derived pep-
tides, representing all T-cell activation inducing epitopes on the 
corresponding allergen. As discussed here, such peptides induce 
T-cell unresponsiveness, and fail to provide B-cell help, resulting in 
IgE synthesis in vitro. They also induce a state of T-cell unrespon-
siveness in mice it, vivo. Because these pep tides do not react with IgE 
antibodies and thus are unable to induce anaphylactic reactions, they 
seem to be ideal tools for inducing specific T-cell tolerance it' vivo. 
The outcome of the clinical trial with the Fel dl - derived peptides 
will provide more information about the efficacy and safety of such 
therapies, although it has to be kept in mind that this trial is carried 
out with only two peptides containing "immunodominant" T-ceJl 
epitopes, whereas the Fel dl molecules contain many more T-cell 
epitopes, which may prevent efficient tolerance induction in all 
patients. 
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ANNOUNCEMENT 
The Ninth Combined Skin Pathology Course and The Fifth Annual Workshop in Dermato-
pathology sponsored by Scripps Clinic and Research Foundation, will be held at the Sheraton 
Grande Torrey Pines Hotel, La Jolla, California, September 17 - 21, 1994. 
The program will be based on a rigorous, comprehensive, and practical review of dermato-
pathology. Microscopic sessions will be conducted, and the workshop approach will include 
demonstration and unknown slides. The course will offer 40 hours of Category I CME credit. 
The Course Director will be James H. Graham, M.D., Head, Division of Dermatopathology. 
For further information contact: Department of Academic Affairs, 403C, Scripps Clinic and 
Research Foundation, 10666 N. Torrey Pines Road, La JoUa, CA 92037. Telephone, (619) 
554-8556; FAX, (619) 554-6310. 
